appliedclinicaltrialsonline8d
FDA Approves Eli Lilly’s Omvoh for Crohn’s Disease Based on Phase III VIVID-1 Trial Outcomes
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
Here are highlights from Tuesday’s Analyst Blog:
Chicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...
BioSpace8d
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
GlobalData on MSN8d
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...
FDA approves Omvoh for moderately to severely active Crohn's disease
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...
BioSpace7d
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
El País in English6d
What are the limits in the fight against obesity? Ozempic owner disappoints the market
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...
Zacks.com on MSN10d
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements ...